Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294896 | 0.88 | ESR2 (0.43) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL1294778 | 0.87 | ESR2 (0.42) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL18648615 | 0.87 | ESR2 (0.42) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL18648623 | 0.87 | ESR2 (0.42) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL1293853 | 0.85 | ESR2 (0.41) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL1295042 | 0.85 | ESR2 (0.41) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL1294501 | 0.84 | ESR2 (0.45) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL12110147 | 0.84 | ESR2 (0.40) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL1294596 | 0.84 | ESR2 (0.40) | ESR2MAPK1NR1H2MEN1KMT2A | |
| SCHEMBL12110430 | 0.83 | ESR2 (0.41) | ESR2MAPK1NR1H2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2546255-B1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| EP-2546255-A1 | BENZAZEPINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885MAPK1 3811/4885NR1H2 1241/4885 |
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | ESR2 185/4885MAPK1 3966/4885NR1H2 881/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885MAPK1 3811/4885NR1H2 1241/4885 |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | ESR2 182/4885MAPK1 3811/4885NR1H2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.